Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) Revenue (2017 - 2025)

UroGen Pharma (URGN) has disclosed Revenue for 9 consecutive years, with $37.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 54.03% year-over-year to $37.8 million, compared with a TTM value of $109.8 million through Dec 2025, up 21.45%, and an annual FY2025 reading of $109.8 million, up 21.45% over the prior year.
  • Revenue was $37.8 million for Q4 2025 at UroGen Pharma, up from $27.5 million in the prior quarter.
  • Across five years, Revenue topped out at $37.8 million in Q4 2025 and bottomed at $7.5 million in Q1 2021.
  • Average Revenue over 5 years is $19.8 million, with a median of $19.5 million recorded in 2024.
  • The sharpest move saw Revenue skyrocketed 3403.23% in 2021, then grew 3.35% in 2024.
  • Year by year, Revenue stood at $16.2 million in 2021, then increased by 11.86% to $18.1 million in 2022, then soared by 30.06% to $23.5 million in 2023, then rose by 4.4% to $24.6 million in 2024, then surged by 54.03% to $37.8 million in 2025.
  • Business Quant data shows Revenue for URGN at $37.8 million in Q4 2025, $27.5 million in Q3 2025, and $24.2 million in Q2 2025.